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POLICY OPTIONS AND OBJECTIVES FOR  
STEM CELL REGULATION 
Shawn H.E. Harmon♠ 
Policy Brief 5:2008 
Drawing on the empirical research conducted at InnoGen and research undertaken at SCRIPT, this Policy Brief places stem cell 
research in the broader bioscience and health research context, highlights what have proven to be effective policy approaches in 
Europe, identifies some core issues in translating policy objectives into legal regulation, and offers several recommendations to 
facilitate the design of effective human tissue (and stem cell) regulation in Argentina. 
♠ Research Fellow, AHRC/SCRIPT and ESRC/InnoGen, University of Edinburgh; Principle 
Investigator on ESRC-funded “Governing Emerging Technologies: Social Values in Stem Cell 
Regulation in Argentina” (Award RES-000-22-2678); Member of the Nova Scotia Bar; BA, 
Saint Mary’s University, Canada (1993); LLB, University of New Brunswick, Canada (1996); 
LLM, University of Edinburgh, UK (2004). 
1 H. Greenwood et al., “Regenerative Medicine: New Opportunities for Developing Countries” 
(2006) 8 International Journal of Biotechnology 60-77. 
BIOSCIENCES, HEALTH AND EXPECTATION 
 
It is widely believed that biosciences (and resultant biotechnologies) are critical 
to social and economic life in the new, globalised world.  Indeed, both national 
and supra-national governments are now seeking to use the bioscience 
industry as an engine for growth and competitiveness.  This is especially so in 
the healthcare context, where sci-tech innovations are viewed as change-
instigators; they are influencing our ideas of what is or might be possible from 
a health perspective, and they are increasingly shaping how we investigate 
health and how we structure healthcare delivery. 
 
Within this healthcare context, the concept of regenerative medicine has 
proven very appealing and very mobilising (to industry, policy-makers and the 
polity more generally).  Regenerative medicine is an emerging interdisciplinary 
field of research and clinical applications focused on the repair, replacement or 
regeneration of cells, tissues or organs to restore impaired function.  It 
implicates soluble molecules, gene therapy, stem cell transplantation, tissue 
engineering and cell reprogramming.1  
 
As evidenced by the above definition, a key component of regenerative 
medicine (and of our bioscience future more generally) is stem cell research 
(SCR) and innovations resulting from same.  Generally, stem cells (SC) are 
basic cells which can give rise to specialised cells, and they are divided into 
adult or somatic stem cells (SSC), which are derived from particular tissue such 
as bone marrow or blood, and embryonic stem cells (ESC), which are derived 
from early stage embryos. 
 
POLICY-MAKING PROCESSES 
 
Modern biosciences – which incite repercussions that are potentially deep 
(extreme and fundamental) and long (slow-burning and long-lasting) – require  
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2. A fact which Argentina has recognised as evidenced by its recent action in the sci-tech field.
3. For more on this, see C. Lyall, “Governing Genomics: New Governance Tools for New 
Technologies”, Briefing No. 9, 2007, at 
http://www.genomicsnetwork.ac.uk/media/governing%20genomics.pdf 
4. This empirical research, undertaken by InnoGen, comprised interviews with approximately 70 
professionals (academic and industry researchers and clinicians in the UK and Australia): see A. 
Bruce & N. Marks, “Five Myths About Human Embryonic Stem Cell Research”, Briefing No. 14, 
2007, at 
http://www.genomicsnetwork.ac.uk/media/five%20myths%20about%20human%20embryonic
%20stem%20cell%20research.pdf. 
something stronger than self-regulation,2 and this is certainly the case in the 
promising but controversial field of SCR.  However, the biosciences have also 
resulted in a general questioning of traditional top-down, hierarchical 
approaches to policy and regulation-making.  Policy objectives are more likely 
to be (effectively) realised when key stakeholders (legislature, public agencies, 
industry, non-governmental interests, civil society more broadly) are engaged 
in the development of policy. 
 
The inclusive and interactive process often called for is characterised as 
“governance” rather than “government”; it is a policy-making process which 
proceeds via multiple actors, both governmental and non-governmental, so as 
to facilitate the formation of productive relationships and networks, and to 
promote democratic processes and more nuanced policy responses.3  The 
state facilitates interaction among various interests while taking steps to 
ensure that no single actor (eg: the church, or industry as represented by 
multinational corporations) dominates the process.  This can be done through 
thoughtful framing and equitable gate-keeping of the discussion. 
 
In Argentina, the gate-keeping function of the governance process is 
appropriately managed jointly and collaboratively by the Ministries of Health 
and of Science & Technology, which have both identified core objectives and 
framing themes for the science. 
 
TENSIONS IN THE STEM CELL ENVIRONMENT 
 
Of course, adopting a governance approach requires the state to be prepared 
to deal with diversity and complexity.  Some of this diversity/complexity may 
stem from the fragmented nature of government itself (ie: government is not 
a monolithic entity and therefore may have conflicting priorities for 
innovation promotion, on the one hand, and risk regulation on the other), but 
much of it will stem from the increased evidence derived from stakeholders.  
An example of the diversity which might be expected in the SC context is 
suggested by research that has already been undertaken. 
 
Although debates around human ESCR are often portrayed as polarised 
conflict between several camps - most notably scientists, who see embryos as 
a cluster of cells and seek enablement, versus religiously-motivated groups, 
who see embryos as morally equivalent to adult humans and wish to halt 
research - this characterisation appears to be unfounded.  Empirical research 
examining the positions of professionals operating in this field in the UK and 
Australia suggests the following: 4 
 
• Not all stem cell scientists are positive about the therapeutic prospects 
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5. For example, note the contradictions apparent in the abortion setting: see L. Acero, “Gender and 
the New Reproductive Technologies in Latin America” (2006) 49 Development 135-140.  These 
(cultural) contradictions are also discussed briefly in S. Harmon, “Emerging Technologies and 
Developing Countries: Stem Cell Research (and Cloning) Regulation and Argentina” (2008) 
forthcoming in Developing World Bioethics. 
6. This has certainly been demonstrated in the pharmaceutical sector where the incremental 
accumulation of (increasingly) burdensome regulations have all but entrenched an expensive 
innovation model that has marginalised the role played by small and medium sized biotech 
entities: see J. Tait et al., “Governance, Policy and Industry Strategies: Agro-Biotechnology and 
Pharmaceuticals” in M. Mazzucato & G. Dosi (eds.), Knowledge Accumulation and Industry 
Evolution (Cambridge, CUP, 2006) 378-401, and J. Chataway et al., “The Governance of Agro- 
and Pharmaceutical Biotechnology Innovation: Public Policy and Industrial Strategy” (2006) 18 
Technology Analysis & Strategic Management 17. 
for ESCR; some see adult and ESCR as complimentary.  Moreover, 
optimism over the therapeutic prospects of ESCR is muted in part 
because of the perceived gap between experimental results and clinical 
reality.  As such, despite their excitement, many scientists wish not to 
raise the expectations of patients unrealistically. 
 
• Many stem cell scientists believe the benefits of ESCR will come not 
from therapies (as widely expected), but in the form of contributions 
to basic science, human disease modelling, bioreactor development, 
pharmaceutical toxicity screening, and harnessing the body’s own 
regenerative capacities. 
 
• Not all opponents of ESCR base their views on their religious beliefs, 
and not all stem cell scientists were non-religious. 
 
• Positions on ESCR are grounded on a wider variety of issues than the 
moral status of the embryo.  Even those who view the embryo as a 
ball of cells felt that it should be treated with respect, and that its 
destruction has to be carefully weighed against the value of potentially 
important health applications.  Other moral issues include unnecessary 
hype, commercialisation of the human body, coercion and 
instrumentalisation of the female body, exploiting poor people, 
difficulty with obtaining consent, maverick scientists performing 
clinical trials too early, and high costs. 
 
In short, (moral) uncertainty about hESCR does not derive solely from 
religious beliefs, and not all religious people are against hESCR.  Moreover, 
there are issues other than the moral status of the embryo that will determine 
people’s ultimate assessment of the propriety of the science.  We can 
anticipate that this reality will be born out in Argentina.5 
 
A policy-making process which captures this diversity and richness of opinion 
will offer a broader and more creative base from which to adapt regulation, 
which will concomitantly, address a wider range of concerns.  It will also go 
some way to avoiding the unhelpful factionism identified above. 
 
FROM POLICY TO REGULATION 
 
Through its quality, safety and effectiveness standards, and its influence on 
corporate strategy and sector dynamism, regulation has an important impact 
on the operation of (industrial) sectors and the kinds of products that are 
ultimately developed by that sector.6  The regulatory system that is fashioned 
and how (well) it interacts with other related regimes (such as corporate 
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7. Of course, one must concede the uncertainty around trying to predict future technologies, their 
potential policy impacts, and their interactions with complex systems.  One must also recognise 
that the manner of the administration of policy (and concomitant regulations) will have profound 
effects. 
8. If Argentina wishes to maximise its benefit from its bioscience innovation (and therefore its 
bioscience regulation), it might also consider ways in which it might improve regional 
infrastructure and therefore conditions for bioscience innovation so that it retains a regional 
competitive advantage.   For more on the regional element of innovation, see T. Papaionnou, 
“Regional Innovation and Pubic Policy”, Briefing No. 13, 2007, at 
http://www.genomicsnetwork.ac.uk/media/regional%20innovation%20and%20public%20policy
.pdf. 
9. The benefits of early inclusion of these broader considerations is supported by empirical research 
conducted by InnoGen in the area of bioscience innovation: see T. Papaionnou, “Building 
Innovative Capabilities Through Pubic-Private Collaboration in Genomics and Biotechnology”, 
Briefing No. 12, 2007, at 
http://www.genomicsnetwork.ac.uk/media/building%20innovative%20capabilities.pdf. 
10. Such was recommended by J. Tait, J. Chataway & D. Wield, “Appropriate Governance of the Life 
Sciences – 2: The Case for Smart Regulation”, InnoGen Policy Brief, 2008, who state that 
enabling criterion will affect the speed with which a particular regulatory policy is able to exert its 
influence, while the extent and appropriateness of its discrimination among outputs/products will 
influence its effectiveness in guiding product/process development in particular areas. 
11. For a consideration of how risk was approached differently in the GM crop context as between 
the EU and the USA, with the consequence of dramatically different  trajectories for the industry, 
see J. Tait, “Risk Governance of Genetically Modified Crops”, Briefing No. 11, 2007, at 
http://www.genomicsnetwork.ac.uk/media/risk%20governance%20of%20genetically%20modifi
ed%20crops.pdf 
governance, intellectual property protection, etc.) will, in no small part, 
determine who takes the lead in conducting ESCR and developing SC 
products in Argentina (eg: multinationals, or smaller, more dynamic 
companies, or more socially-responsive public-private partnerships).  If the 
system is too complex and therefore too onerous, many potential players will 
be squeezed out. 
 
As such, in formulating its regulation, Argentina must be clear about its policy 
goals (ie: it must imagine a good/ideal outcome for society, for public health, 
for sci-tech innovation, and for the industries implicated, and fashion a 
regulatory framework that makes it possible).7  It must recognise that the 
regulation will constitute a component of a broader innovation and health 
delivery landscape with both formal and informal elements, and which must 
meet both Argentine and regional needs;8 it must identify the links between 
its socio-economic, innovation, and health objectives and understand them as 
integrated entities.9  In short, it must strive for a degree of “joined upness” so 
that actions at one healthcare innovation focal point (eg: ESCR) do not cause 
unanticipated problems at another (eg: human trials or commercialisation), 
each of which will have unique, context-dependent issues, players and risks. 
 
Given the above, in determining its way forward in the SCR context, 
Argentina might consider those regulatory systems that already exist and that 
are relevant to this arena (eg: the human tissue and transplantation regime, 
the intellectual property regime, etc.), ensuring that they are complimentary 
and, between them, do not create unnecessary complexity.  Additionally, 
Argentina should consider adopting regulation that enables changes in industry 
strategies, discriminates amongst outputs/products on socially relevant criteria 
so as to promote effectiveness and efficiency,10 and, though being 
meticulously risk-aware, does not dwell overly much on risk-based 
constraints.11 
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RECOMMENDATIONS FOR ARGENTINA 
 
Based on evidence obtained by InnoGen through a variety of projects, we can 
make the following recommendations: 
Policy-makers 
should be 
prepared to deal 
with complexity 
and 
contradictions. 
 
 
• Policy-makers should to be prepared to deal with contradiction (ie: 
tensions within the opinions held by single stakeholders) and 
therefore complexity.  As such, broad consultation combined with 
careful framing may help Argentina avoid the simplistic and polarising 
debate that has emerged in too many settings, as will the giving of 
space to thoughtful stakeholders to express their concerns without 
fear of jeopardising the SCR agenda. 
 
• Policy-makers should be prepared to frame the context within which 
the policy debates unfold (ie: write the lexicon, capture the 
imagination, and temper the expectation relating to the science, while 
engaging with concerns and desires expressed by the stakeholders and 
networks which choose or are invited to participate). 
 
• Policy-makers should appreciate that the primary benefits from 
hESCR may come in areas such as basic science, toxicity screening 
and drug development rather than cell therapies, and that benefits will 
probably be mostly medium and long term, not immediate.  As such, 
hyperbole and (easier) short-term planning should be avoided so as to 
encourage more durable and flexible policy options. 
Policy-makers 
should 
understand that 
therapies may 
not be the most 
beneficial 
outcome of stem 
cell research 
 
• Policy-makers should make every effort to adopt a “joined up” 
approach; they need to be aware of the myriad ways in which SCR and 
its regulation interacts with other existing, emerging or planned 
regulatory mechanisms, and they must, of course, be careful to do so 
without making the endeavour too complex and burdensome. 
 
Regulation is not only an instrumental tool for achieving particular ends, but 
also a social and cultural phenomenon with its own (geographically and 
jurisdictionally) unique institutions, processes, concepts and ethos.  As such, 
although not every recommendation will be exactly apposite, they are relevant 
not only for Argentina, but for the broader Latin American setting.  
Ultimately, they are founded on sound research in settings with which 
Argentina (and Latin America) will wish to interact and/or emulate. 
Policy-makers 
should consider 
the place of 
stem cell 
research 
regulation 
within the 
constellation of 
relevant fields. 
 
 
This Policy Brief forms part of the programme of work of the 
“Governing Emerging Technologies: Social Values and Stem 
Cell Regulation in Argentina” project funded by the ESRC 
(Award No. RES-000-22-2678) and supported by 
AHRC/SCRIPT and InnoGen.   
For more on the GET: Social Values project, visit  
http://www.law.ed.ac.uk/ahrc/esrcvaluesproject/relatedproject  
